Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [2] Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
    Rogado, J.
    Fenor De La Maza, M. D.
    Pacheco-Barcia, V.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Ballesteros, A.
    Mondejar, R.
    Donnay, O.
    Obispo, B.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2107 - S2108
  • [3] Treatment and prognosis of advanced stage non-small-cell lung cancer
    Ben Abdallah, F. Chermiti
    Ben Ali, G.
    Boudaya, M. Sadok
    Mlika, M.
    Chtourou, A.
    Taktak, S.
    Ben Kheder, A.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (03) : 214 - 220
  • [4] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    [J]. LUNG CANCER, 2012, 77 : S13 - S14
  • [5] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [6] Duration of nivolumab for pretreated, advanced non-small-cell lung cancer
    Geier, Margaux
    Descourt, Renaud
    Corre, Romain
    Leveiller, Guillaume
    Lamy, Regine
    Goarant, Eric
    Bizec, Jean-Louis
    Bernier, Cyril
    Quere, Gilles
    Amrane, Karim
    Gaye, Elisabeth
    Lucia, Francois
    Burte, Emilie
    Chouaid, Christos
    Robinet, Gilles
    [J]. CANCER MEDICINE, 2020, 9 (19): : 6923 - 6932
  • [7] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2020 - 2031
  • [8] NSCLC PDX model for the evaluation of immuno-oncological treatment strategies
    Oswald, Eva
    Klingner, Kerstin
    Lenhard, Dorothee
    Niedermann, Gabriele
    Schueler, Julia B.
    [J]. CANCER RESEARCH, 2015, 75
  • [9] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, Stephen
    Snzol, Mario
    Harbison, Christopher T.
    Kollia, Gerogia D.
    Gupta, Ashok
    Gettinger, Scott N.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157
  • [10] Nivolumab after Progression to Platinum- Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Lopez Flores, M.
    Diz Tain, P.
    Delgado Sillero, I.
    Sanchez Cousido, L.
    Lopez Gonzalez, A.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Garcia Casabal, F.
    De Sande Gonzalez, L.
    Garcia Palomo, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1916 - S1917
12345